Filed pursuant to Rule 424(b)(3)
Registration No. 333-226239
PROSPECTUS SUPPLEMENT
(To
Prospectus dated August 8, 2018)
INTELLIPHARMACEUTICS INTERNATIONAL INC.
6,858,334 Common Shares
This
Prospectus Supplement No. 1 (this "Prospectus Supplement") amends
and supplements our Prospectus dated August 8, 2018 (the
"Prospectus"), which forms a part of our Registration Statement
(our "Registration Statement") on Form F-1 (Registration No.
333-226239). This Prospectus Supplement is being filed to amend and
supplement the information included or incorporated by reference in
the Prospectus with the information contained in this Prospectus
Supplement. The Prospectus and this Prospectus Supplement relate to
the resale, from time to time, of up to 6,858,334 common shares by
certain of our shareholders identified in the
Prospectus.
This
Prospectus Supplement includes information from our Report on Form
6-K, which was filed with the Securities and Exchange Commission on
August 15,
2018.
This
Prospectus Supplement should be read in conjunction with the
Prospectus that was previously filed, except to the extent that the
information in this Prospectus Supplement updates and supersedes
the information contained in the Prospectus.
NEITHER
THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE "SEC") NOR ANY
STATE SECURITIES COMMISSION OR CANADIAN SECURITIES REGULATOR HAS
APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS
PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE
CONTRARY IS A CRIMINAL OFFENSE.
_______________
The
date of this Prospectus Supplement is August 15, 2018
Special Meeting Results
On
August 15, 2018, Intellipharmaceutics International Inc. (the
"Company") held special meeting of shareholders (the "Meeting"). At
the Meeting, shareholders of the Company approved a special
resolution granting our Board of Directors discretionary authority
to implement a consolidation of the issued and outstanding common
shares of the Company on the basis of a consolidation ratio to be
selected by the directors of the Company within a range between
five (5) pre-consolidation common shares for one (1)
post-consolidation common share and 15 pre-consolidation common
shares for one (1) post-consolidation common share, all as more
particularly described in the Management Information Circular of
the Company dated July 6, 2018 included as Exhibit 99.2 to the
Company’s report on Form 6-K furnished to the U.S. Securities
and Exchange Commission on July 13, 2018 (a "reverse
split").
No
decision has been made yet by the Board of Directors of the Company
to implement a reverse split.